Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Cirqle Biomedical Contraception ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   0.0% 26.0% 16.1% 31.5% 7.0% 7.4% 7.7% 7.7%   Credit score (0-100)   0 3 11 1 34 32 32 32   Credit rating   N/A B BB C BBB BB BB BB   Credit limit (kDKK)   0.0 -0.0 0.0 -0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   0.0 -1,094 -4,133 -5,696 62,142 -12,848 0.0 0.0   EBITDA   0.0 -2,312 -6,315 -8,499 58,743 -21,228 0.0 0.0   EBIT   0.0 -2,312 -6,315 -8,499 58,743 -21,236 0.0 0.0   Pre-tax profit (PTP)   0.0 -2,512.0 -6,715.0 -8,781.0 58,368.0 -20,788.0 0.0 0.0   Net earnings   0.0 -2,095.0 -5,558.0 -7,208.0 47,682.0 -15,984.8 0.0 0.0   Pre-tax profit without non-rec. items   0.0 -2,512 -6,715 -8,781 58,368 -20,788 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 51.8 0.0 0.0   Shareholders equity total   0.0 -2,094 2,844 -4,363 50,350 34,366 34,322 34,322   Interest-bearing liabilities   0.0 7,483 0.0 0.0 0.0 184 0.0 0.0   Balance sheet total (assets)   0.0 6,479 10,784 3,629 70,219 45,936 34,322 34,322   Net Debt   0.0 1,505 -9,037 -1,512 -57,460 -39,630 -34,322 -34,322     See the entire balance sheet 1000.0 Volume  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   0.0 -1,094 -4,133 -5,696 62,142 -12,848 0.0 0.0   Gross profit growth   0.0% 0.0% -277.8% -37.8% 0.0% 0.0% 0.0% 0.0%   Employees   0 3 5 5 5 9 0 0   Employee growth %   0.0% 0.0% 66.7% 0.0% 0.0% 80.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   0 6,479 10,784 3,629 70,219 45,936 34,322 34,322   Balance sheet change%   0.0% 0.0% 66.4% -66.3% 1,834.9% -34.6% -25.3% 0.0%   Added value   0.0 -2,312.0 -6,315.0 -8,499.0 58,743.0 -21,227.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 43 -52 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   0.0 -1.0 -2.0 -3.0 1.0 -1.0 0.0 0.0   1000.0 Profitability  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   0.0% 211.3% 152.8% 149.2% 94.5% 165.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   0.0% -27.0% -65.2% -90.5% 150.4% -34.8% 0.0% 0.0%   ROI %   0.0% -30.7% -72.7% -100.1% 204.6% -47.6% 0.0% 0.0%   ROE %   0.0% -32.3% -119.2% -222.7% 176.7% -37.7% 0.0% 0.0%   1000.0 Solidity  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   0.0% -24.4% 26.4% -54.6% 71.7% 74.8% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   0.0% -65.1% 143.1% 17.8% -97.8% 186.7% 0.0% 0.0%   Gearing %   0.0% -357.4% 0.0% 0.0% 0.0% 0.5% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 5.3% 10.8% 0.0% 0.0% 644.0% 0.0% 0.0%   1000.0 Liquidity  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.0 6.2 11.5 4.1 5.7 13.0 0.0 0.0   Current Ratio   0.0 6.2 11.5 4.1 5.7 13.0 0.0 0.0   Cash and cash equivalent   0.0 5,978.0 9,037.0 1,512.0 57,460.0 39,814.0 0.0 0.0   1000.0 Capital use efficiency  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   0.0 5,429.0 9,844.0 2,717.0 57,717.0 41,903.7 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 -771 -1,263 -1,700 11,749 -2,359 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 -771 -1,263 -1,700 11,749 -2,359 0 0   EBIT / employee   0 -771 -1,263 -1,700 11,749 -2,360 0 0   Net earnings / employee   0 -698 -1,112 -1,442 9,536 -1,776 0 0